In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews

Executive Summary

This Month's Profile Group: VC-Backed GI Start-Ups See Opportunity In IBS features profiles of Altheus, AltheRx, Ardelyx and Second Genome. Plus these Start-Ups Across Health Care: InfraScan, PlaqueTec, Prosonix and Veracyte.

You may also be interested in...



InfraScan Inc.

InfraScan Inc. has developed a handheld device for detecting bleeding in the brain in head trauma patients. Such trauma typically causes blood from ruptured vessels to pool in the skull cavity. The trapped blood compresses the brain and increases intracranial pressure, which leads to brain damage. However by beaming near-infrared light at the brain and then analyzing the light reflected back at the device, the Infrascanner reveals the presence or non-presence of an intracranial hematoma, for triage or follow-up diagnostics.

PlaqueTec Ltd.

Cambridge, UK-based PlaqueTec Ltd. is developing a coronary artery blood sampling technology combined with biomarker analysis to map the biological processes associated with the development and rupture of vulnerable plaque. The ambitious young company plans to use this information to detect and monitor plaque biomarkers, and then use these patented data to help identify drug candidates for atherosclerosis.

Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

Related Companies

UsernamePublicRestriction

Register

IV003726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel